Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 3,045 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Long Term Clear all
Completed Phase 2 Interventional Results available

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

NCT00845026
View directory record Official record
Conditions
Schizophrenia
Interventions
LY2140023, aripiprazole, olanzapine, risperidone
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Escondido, California • Garden Grove, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 15, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Results available

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

NCT01369225
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AAB-003 (PF-05236812)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 90 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
15
States / cities
Hallandale, Florida • Ocala, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 15, 2026, 4:17 PM EDT
Completed No phase listed Observational

Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection

NCT01350648
View directory record Official record
Conditions
Hepatitis B, Hepatitis C, HIV-HCV Co-Infection
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 99 Years
Enrollment
569 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 15, 2026, 4:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhance Wellness for Individuals With Long-Term Physical Disabilities

NCT02815878
View directory record Official record
Conditions
Multiple Sclerosis, Muscular Dystrophy, Post-polio Syndrome, Spinal Cord Injury
Interventions
Enhance Wellness
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
45 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 15, 2026, 4:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

StimRouter Registry Clinical Protocol

NCT03913689
View directory record Official record
Conditions
Chronic Pain, Peripheral Neuropathy, Nervous System Diseases, Peripheral Nervous System Diseases, Peripheral Nervous System Problem, Peripheral Nerve Injuries, Peripheral Nervous
Interventions
StimRouter Neuromodulation System
Device
Lead sponsor
Bioness Inc
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
9
States / cities
La Jolla, California • Larkspur, California • Redwood City, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 15, 2026, 4:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluate the Efficacy of a Silk-Like Fabric for the Prevention of Pressure Sores in a Long Term Care Setting

NCT01403272
View directory record Official record
Conditions
Pressure Ulcers
Interventions
DermaTherapy® Linen and underpads.
Device
Lead sponsor
Precision Fabrics Group, Inc.
Other
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2011 · Synced Oct 15, 2026, 4:17 PM EDT
Completed Phase 3 Interventional Results available

Long Term Open Label Continuation Study

NCT00195650
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
74
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2012 · Synced Oct 15, 2026, 4:17 PM EDT
Completed Phase 3 Interventional Results available

A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children

NCT00159874
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sildenafil citrate
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
11
States / cities
Palo Alto, California • Stanford, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 15, 2026, 4:17 PM EDT
Completed Phase 3 Interventional Results available

Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)

NCT00947297
View directory record Official record
Conditions
Urea Cycle Disorders
Interventions
HPN-100
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
21
States / cities
Long Beach, California • Los Angeles, California • Stanford, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 15, 2026, 4:17 PM EDT
Completed Phase 3 Interventional Results available

Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy

NCT01364597
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam (BRV)
Drug
Lead sponsor
UCB Pharma SA
Industry
Eligibility
28 Days to 17 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
15
States / cities
Los Angeles, California • Gulf Breeze, Florida • Wellington, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 15, 2026, 4:17 PM EDT
Completed No phase listed Observational

Juvenile Idiopathic Arthritis (JIA) Registry

NCT00783510
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis, JIA
Interventions
adalimumab, Methotrexate
Biological · Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 17 Years
Enrollment
849 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2024
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 15, 2026, 4:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Chemotherapy-Induced Changes to Cognition and DNA in Breast Cancer Survivors

NCT00496613
View directory record Official record
Conditions
Breast Cancer, Long-Term Survivors
Interventions
Mini-Mental State Exam and Blood Draw
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2022
U.S. locations
3
States / cities
Commack, New York • New York, New York • Rockville Centre, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 15, 2026, 4:17 PM EDT
Active, not recruiting No phase listed Observational

Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms

NCT00443274
View directory record Official record
Conditions
Breast Implant
Interventions
NBIR - US National Breast Implant Registry, 410 Arm, BIFs - Breast Implant Follow-Up Study
Other · Device
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
56,460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2029
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 15, 2026, 4:17 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes

NCT03923374
View directory record Official record
Conditions
Opioid-use Disorder, Opioid Use, Unspecified, Buprenorphine Dependence
Interventions
Subutex / Buprenorphine, Fetal & Neonatal MRI, DNA/Genetic/Pharmacokenetic Blood Draws
Drug · Diagnostic Test
Lead sponsor
Senthil Sadhasivam
Other
Eligibility
18 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 15, 2026, 4:17 PM EDT
Terminated Not applicable Interventional

Evaluation of the 24/7 EEG SubQ System for Ultra Long-Term Recording of Patients With Epilepsy Involving the Temporal Lobe Region.

NCT04526418
View directory record Official record
Conditions
Epilepsy
Interventions
24/7 EEG™ SubQ system
Device
Lead sponsor
UNEEG Medical A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
9
States / cities
Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 15, 2026, 4:17 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT02836418
View directory record Official record
Conditions
Facioscapulohumeral Muscular Dystrophy, Limb Girdle Muscular Dystrophy
Interventions
ATYR1940
Drug
Lead sponsor
aTyr Pharma, Inc.
Industry
Eligibility
16 Years to 25 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Irvine, California • Stanford, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 15, 2026, 4:17 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773

NCT01395810
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia B
Interventions
nonacog beta pegol
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
13 Years to 70 Years · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 15, 2026, 4:17 PM EDT
Terminated Not applicable Interventional Results available

Assessment Of The Effects Of Short and Long Term Use Of CPAP

NCT00592631
View directory record Official record
Conditions
Asthma
Interventions
CPAP-Continuous Positive Airway Pressure, SHAM
Device
Lead sponsor
Indiana University
Other
Eligibility
8 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 10, 2016 · Synced Oct 15, 2026, 4:17 PM EDT
Terminated Phase 3 Interventional

A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency

NCT03145831
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Somavaratan
Drug
Lead sponsor
Versartis Inc.
Industry
Eligibility
3 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 15, 2026, 4:17 PM EDT
Completed Phase 3 Interventional Results available

A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder

NCT02436239
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vilazodone
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
7 Years to 17 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
54
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 15, 2026, 4:17 PM EDT
Recruiting No phase listed Observational

A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

NCT05820672
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
No intervention
Other
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
Not listed
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
27
States / cities
Phoenix, Arizona • Orange, California • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 15, 2026, 4:17 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion

NCT00264914
View directory record Official record
Conditions
Inappropriate ADH Syndrome, Hyponatremia
Interventions
SR121463B
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 15, 2026, 4:17 PM EDT
Recruiting Phase 3 Interventional

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

NCT06405087
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Vedolizumab SC, No Intervention
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 17 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
13
States / cities
Phoenix, Arizona • Loma Linda, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 15, 2026, 4:17 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal Antibody

NCT02069899
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytosis
Interventions
Emapalumab
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
Not listed
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
5
States / cities
Grand Rapids, Michigan • Chapel Hill, North Carolina • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 15, 2026, 4:17 PM EDT